Sirolimus inhibits cell proliferation and downregulates mTOR and HIF-1α expression in human hepatic carcinoma HepG2 cells

World Chinese Journal of Digestology

Volumn 17, Issue 31, 2009, Pages 3241-3243

  Wang, Yu ^a   Xiong, Jing ^a   Cheng, Hen Hui ^a   Zhou, Sheng ^a   Zhao, Qiu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Hepatic carcinooma; Hypoxia inducible factor 1 ; Mammalian target of rapamycin; Sirolimus

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; RAPAMYCIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; DRUG MECHANISM; HUMAN; HUMAN CELL; LIVER CARCINOMA; PROTEIN EXPRESSION; WESTERN BLOTTING;

EID: 75349099127     PISSN: 10093079     EISSN: None     Source Type: Journal    
DOI: 10.11569/wcjd.v17.i31.3241     Document Type: Article

References (16)

1. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000; 103: 253-262
2. Huang S, Houghton PJ. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 2002; 3: 295-304
3. Chen F, Omasa M, Kondo N, Fujinaga T, Shoji T, Sakai H, Bando T. Sirolimus treatment for recurrent lymphangioleiomyomatosis after lung transplantation. Ann Thorac Surg 2009; 87: e6-e7
4. Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926-1945
5. Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19: 6680-6686
6. Benito AI , Furlong T, Martin PJ , Anasetti C, Appelbaum FR , Doney K, Nash RA, Papayannopoulou T, Storb R, Sullivan KM, Witherspoon R, Deeg HJ. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versushost disease. Transplantation 2001; 72: 1924-1929
7. Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo. Anticancer Res 2008; 28: 3801-3808
8. Vignot S, Faivre S, Aguirre D, Raymond E. mTORtargeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525-537
9. Pene F, Claessens YE, Muller O, Viguié F, Mayeux P, Dreyfus F, Lacombe C, Bouscary D. Role of the phosphatidylinositol 3-kinase/Akt and mTOR/ P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma. Oncogene 2002; 21: 6587-6597
10. Semenza GL. HIF-1: mediator of physiological and pathophysiological responses to hypoxia. J Appl Physiol 2000; 88: 1474-1480
11. Carmeliet P, Dor Y, Herbert JM, Fukumura D, Brusselmans K, Dewerchin M, Neeman M, Bono F, Abramovitch R, Maxwell P, Koch CJ, Ratcliffe P, Moons L, Jain RK, Collen D, Keshert E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998; 394: 485-490
12. Jung HJ, Park JW, Lee JS, Lee SR, Jang BC, Suh SI, Suh MH, Baek WK. Silibinin inhibits expression of HIF-1alpha through suppression of protein translation in prostate cancer cells. Biochem Biophys Res Commun 2009; 390: 71-76
13. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721-732
14. Wang W, Xu GL, Jia WD, Wang ZH, Li JS, Ma JL, Ge YS, Xie SX, Yu JH. Expression and correlation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor and microvessel density in experimental rat hepatocarcinogenesis. J Int Med Res 2009; 37: 417-425
15. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-713
16. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 2002; 22: 7004-7014